{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:41:59Z","timestamp":1794638519579,"version":"4.9.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105435","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:41:13Z","timestamp":1781800873000},"page":"105435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anticancer drug dosing: Balancing benefit and toxicity"],"prefix":"10.1016","volume":"226","author":[{"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.critrevonc.2026.105435_bib1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cpt.3685","article-title":"Implementing pre-emptive pharmacogenetics: impact of early pharmacogenetic screening in a pediatric oncology cohort of 1,151 subjects","volume":"118","author":"Bernsen","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105435_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-101053","article-title":"Views of European Union medicine regulators and healthcare professionals on the approved versus prescribed dose of protein kinase inhibitors: an interview study","volume":"15","author":"Brinkhof","year":"2025","journal-title":"BMJ Open."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105435_bib3","doi-asserted-by":"crossref","first-page":"11042","DOI":"10.1200\/JCO.2025.43.16_suppl.11042","article-title":"Sex-based differences in clinical outcomes for solid tumours: a pooled IPD meta-analysis of contemporary anticancer drug trials","volume":"43","author":"Chhetri","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105435_bib4","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Fourie Zirkelbach","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105435_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FTD.0000000000000654","article-title":"Therapeutic drug monitoring of oral anticancer drugs: the Dutch Pharmacology Oncology Group\u2013therapeutic drug monitoring protocol for a prospective study","volume":"41","author":"Groenland","year":"2019","journal-title":"Ther. Drug. Monit."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105435_bib6","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3390\/pharmaceutics17111452","article-title":"Practical pharmacokinetic\u2013pharmacodynamic models in oncology","volume":"17","author":"Guan","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2026.105435_bib7","article-title":"Project Optimus: principles, challenges, and a paradigm shift in dose optimization for cancer therapies","author":"Hojouj","year":"2025","journal-title":"Zenodo"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105435_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/psp4.12588","article-title":"Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology","volume":"10","author":"Maier","year":"2021","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105435_bib9","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.3390\/cancers17193262","article-title":"Optimizing anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring","volume":"17","author":"Monteiro","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105435_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.70072","article-title":"Estimands for early-phase dose optimization trials in oncology","volume":"67","author":"Mukherjee","year":"2025","journal-title":"Biom. J."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105435_bib11","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/cancers15123233","article-title":"Dose optimization in oncology drug development: the emerging role of pharmacogenomics, pharmacokinetics, and pharmacodynamics","volume":"15","author":"Papachristos","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105435_bib12","article-title":"Therapeutic drug monitoring for cytotoxic anticancer drugs: principles and evidence-based practices","volume":"12","author":"Pattanaik","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105435_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-025-04823-3","article-title":"Sacituzumab govitecan initial dose reduction in Polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety","volume":"95","author":"Pieni\u0105\u017cek","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105435_bib14","first-page":"92","article-title":"Importance of sex-dependent differences for dosing selection and optimization of chemotherapeutic drugs","volume":"70","author":"Seydoux","year":"2025","journal-title":"Chemotherapy"},{"key":"10.1016\/j.critrevonc.2026.105435_bib15","unstructured":"Shimamura H., Lee H.Y., Thall J., et al. Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology. arXiv. Preprint posted November 13, 2024. arXiv:2411.08698."},{"key":"10.1016\/j.critrevonc.2026.105435_bib16","article-title":"The role of precision dosing and therapeutic drug monitoring in precision oncology: a single-centre experience with everolimus","author":"Tan","year":"2026","journal-title":"J. Curr. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105435_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf311","article-title":"Clinical perspective on management of key adverse events with sacituzumab govitecan","volume":"30","author":"Tolaney","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105435_bib18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/FTD.0000000000001391","article-title":"Therapeutic drug monitoring of oral targeted anticancer drugs: achievements, experiences, challenges, and the path forward","volume":"47","author":"van der Kleij","year":"2025","journal-title":"Ther. Drug. Monit."},{"key":"10.1016\/j.critrevonc.2026.105435_bib19","article-title":"Polypharmacy driven synergistic toxicities in elderly breast cancer chemotherapy drug management and adverse drug reactions: a mini review","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105435_bib20","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/jpm15110516","article-title":"The three musketeers in cancer therapy: pharmacokinetics, pharmacodynamics and personalised approach","volume":"15","author":"Zari\u0107","year":"2025","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.critrevonc.2026.105435_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3658","article-title":"Oncology dose optimization: tailored approaches to different molecular classes","author":"Zhu","year":"2025","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:41:05Z","timestamp":1793943665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"alternative-id":["S1040842826003227"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105435","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer drug dosing: Balancing benefit and toxicity","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105435","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105435"}}